drugset / Trial / NCT04296279
A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults
Phase 1
Unknown
46 enrolled
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR) · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
A Phase 1, open label clinical study to evaluate the safety, immunogenicity, tolerability and efficacy of Plasmodium falciparum Malaria Protein 014 (FMP014) combined with (ALF with QS-21), saponin molecule derived from the bark of Quillaja species (ALFQ)) in healthy adult volunteers at different doses and dosing schedules.
Timeline
- Start
- 2020-03-20
- Primary completion
- 2021-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ALFQ | Unknown | 0.5 ml | Intramuscular |
| Comparator | ALFQ | Unknown | 1 ml | Intramuscular |
| Comparator | FMP014 | Unknown | 20 ug | Intramuscular |
| Comparator | FMP014 | Unknown | 40 ug | Intramuscular |